Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neflamapimod - CervoMed

Next Previous
Drug Profile

Neflamapimod - CervoMed

Alternative Names: VX-745

Latest Information Update: 22 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer CervoMed; Vertex Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Anti-inflammatories; Antidementias; Benzene derivatives; Chlorobenzenes; Fluorobenzenes; Nootropics; Pyridazines; Pyrimidinones; Small molecules; Sulfides; Vascular disorder therapies
  • Mechanism of Action Mitogen-activated protein kinase 14 inhibitors; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Frontotemporal dementia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Aphasia; Huntington's disease; Lewy body disease; Stroke
  • Phase I Frontotemporal dementia
  • Discontinued Asthma; Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 11 Aug 2025 CervoMed plans to meet with the FDA in the fourth quarter of 2025 for planned phase III trial in Lewy body disease
  • 28 Jul 2025 Efficacy data from phase II RewinD-LB trial released by CervoMed
  • 24 Jun 2025 Phase-II clinical trials in Aphasia in USA (PO) (NCT07033481)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top